**IQVIA**

National Anti-tumor Drug Surveillance System (NATDSS)

China's largest Real World Data network with patient records from 1400 hospitals

The National Anti-Tumor Drug Surveillance System (NATDSS) is the largest Real World Data oncology network in China, leveraging data from 1400+ oncology and general hospitals, with a combined 15 million+ cancer patients since 2013. The NATDSS plays a crucial role in enhancing cancer care, treatment, and research throughout China, providing drug response, treatment outcome, and patient data for analysis, and evidence creation.

About China's Evidence-Based Cancer Care Network

In December 2018, the National Health Commission published notice on monitoring the clinical application of anti-tumor drugs at a national level. The National Cancer Center oversees NATDSS and ensures its effectiveness in improving cancer diagnosis, treatment, and follow-up, contributing to evidence-based cancer care, benefiting patients by providing better access to effective treatments, and researchers by providing clearer information.

Benefits of the National Anti-tumor Drug Surveillance System

Pan-tumor Database

Including oncology patient records regardless of tumor type, providing in-depth patient journey for various oncology research

Geographic Representativeness

Containing patients from different geographic regions of China and provides a rich and diverse sample

Cost-Effectiveness

Reducing the need for primary data collection, lowering research costs and makes studies more financially feasible

Facilitates Collaboration & Networking

Allowing one central Ethics Committee approval to enable collaborations and smoothen operation requirements

# Combining the largest patient coverage and ease of access

Best national representativeness

- Covering all 31 provinces in China
- Including both oncology and general hospitals

Largest oncology patient population

- 1M+ Lung cancer, 800K+ breast cancer, 600K+ gastric cancer, 500K+ liver cancer patients*
- Comprehensive data points from hospital EMR system

Easiest operation process

- 1 centralized ethics committee review
- Proven operation and data access model

Mortality linkage with national CDC

- Unique resource for death related outcomes
- Regular linkage with CDC death registry

The largest real-world oncology data network in China providing nationally representative research data

1400+
Hospitals (onco +general)

400+TB
Data volume with rapid growth

15 mil+
Real cancer patients (since 2013)

Mortality
Evaluable OS outcome

	National level hospitals	Provincial general hospitals	Provincial oncology hospitals	Municipal general hospitals	Municipal oncology hospitals	Other Hospitals	Total
	20	231	28	909	52	245	1495

NATDSS captures comprehensive data elements to enable research studies and deep insights

Patient characteristics

- Age, sex
- Comorbidities
- History of cancer, metastases
- Family history
- Other important elements: e.g., smoking status, menopausal status

Tumor characteristics

- Broad cancer category
- Tumor site
- Stage: T, N, M and grade
- Histology
- Metastatic status
- Metastatic site
- Tumor size and extension
- Lymph node invasion

Testing

- Clinical lab and point-of-care test results
- Type of molecular test performed
- Molecular results
- Expression positive/negative
  » Mutation, with specific alteration and tumor mutation burden
  » Amplification/gain
- Pathology results
- Imaging results

Outcomes

- Overall surivval (OS)
- Adverse/safety events
- Clinician-assessed progression

Treatment

- Treatments before and after diagnosis:
  » Drugs
  » Radiation
  » Surgery
  » Other procedures
- Reason for discontinuation

Resource utilization

- Inpatient visit/hospitalization
- Cost information by category and item
  » Drug cost
  » Procedure cost
  » Hospitalization cost

Various offerings supported by our partnerships to meet clients' R&D, RWE and commercial needs

Safety and epidemiology

- Patient profiling
- Treatment pattern
- Comparative effectiveness
- Saftey

HEOR

- Healthcare resource utilization and costs
- Cost-effectiveness
- Burden of disease

Insight generation

- Patient profiling
- Adherence and persistence
- Drug launch planning and strategy

Trial planning

- Natural history of disease
- External comparator arms
- Clinical trial optimization

IQVIA